Views & Analysis Cost concerns with the new NHS pricing scheme A new pricing scheme, which took effect this month, has raised the cap on NHS spending on branded drugs slightly.
News Another LAG-3 setback as Regeneron drug fails phase 3 trial Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
